Business ❯ Finance ❯ Securities
Class Action Lawsuits Class Action Lawsuit Elon Musk Misleading Statements Class Action Litigation Class Action Corporate Governance False Statements Internal Controls IPOs Lawsuit Investment Losses Investor Rights Securities Class Action Lawsuit Lawsuits Non-GAAP Practices Corporate Fraud Investor Losses SEC Regulations Market Manipulation
The pending Northern District of California case challenges disclosures about Cytokinetics’ aficamten review after an FDA‑requested REMS delayed the timeline.